$7.47
arrow_drop_down1.58%Key Stats | |
---|---|
Open | $7.50 |
Prev. Close | $7.59 |
EPS | -2.72 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $239.41M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 7.33 | 7.71 |
52 Week Range | 3.19 | 11.90 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -2.72 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up - Zacks Investment Research
AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC - Zacks Investment Research
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study